Unlike inclisiran’s siRNA mechanism, VERVE-101 uses an mRNA-encoded adenine base editor plus a guide RNA that specifically targets the PCSK9 gene. Base editing alters a single base pair in the ...
Researchers at Alynylam Pharmaceuticals in Cambridge, Massachusetts, developed an siRNA that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that typically binds and degrades ...